Latest Breaking News On - டெட்ரா சிகிச்சை - Page 1 : comparemela.com
Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession
cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.
Frontotemporal Dementia Market Insights, Epidemiology, Treatment Landscape, Emerging Drugs and Leading Companies
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
An experimental drug intended for Alzheimer s patients seems to improve both language and learning in adults with Fragile X syndrome.
The drug, called BPN14770, increased cognitive scores by about 10% in 30 adult males after 12 weeks, a team reports in the journal
Nature Medicine.
That is enough to change the lives of many people with Fragile X, says Mark Gurney, CEO of Tetra Therapeutics, developer of the medicine. People with Fragile X with an IQ of 40 are typically living with their parents or in an institutional setting, Gurney says. With an IQ of 50, in some cases they re able to ride the bus, they re able to hold a job with some assistance and they re able to function better in their community.
Fragile X syndrome involves changes in the X chromosome, as pictured in the four columns of chromosomes starting on the left. The fifth column, on the far right, shows two normal X chromosomes. Richard J. Green/Science Source
An experimental drug intended for Alzheimer s patients seems to improve both language and learning in adults with Fragile X syndrome.
The drug, called BPN14770, increased cognitive scores by about 10% in 30 adult males after 12 weeks, a team reports in the journal
Nature Medicine.
That is enough to change the lives of many people with Fragile X, says Mark Gurney, CEO of Tetra Therapeutics, developer of the medicine.